Related Experiment Video
Updated: Jan 20, 2026

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions
Published on: December 20, 2017
Exploiting intracellular oncogenic proteins to release cytotoxins
Matthias Schild1, Dennis Gillingham1
1Department of Chemistry, University of Basel 4056 Basel Switzerland dennis.gillingham@unibas.ch.
Abstract:
The success of antibody-drug conjugates has demonstrated the value of targeted delivery strategies for cytotoxic molecules. However, many oncogenic drivers remain inaccessible to antibodies due to their intracellular location, and these drivers are currently mainly addressed using small molecule inhibitors. This work explores repurposing such inhibitors for the intracellular delivery and controlled release of cytotoxic payloads. Using click-to-release chemistry, a pre-targeting strategy was developed where inhibitor-tetrazine conjugates enable selective activation of systemically administered trans-cyclooctene (TCO) caged prodrugs. This concept was demonstrated using the epidermal growth factor receptor (EGFR), a key therapeutic target in non-small cell lung cancer. An afatinib-tetrazine conjugate achieved sufficient intracellular retention in EGFR-overexpressing cells to enable toxicity recovery from a TCO-protected monomethyl auristatin E (MMAE) derivative. Successful intracellular targeting and controlled payload release establish a foundation for expanding the scope of targeted drug delivery to previously inaccessible oncogenic drivers.
Insights
Small molecule inhibitors are repurposed for targeted intracellular drug delivery. This strategy uses inhibitor-tetrazine conjugates to activate TCO-caged prodrugs, enabling controlled release of cytotoxic payloads for cancer therapy.
Area of Science:
- Oncology
- Medicinal Chemistry
- Molecular Biology
Background:
- Antibody-drug conjugates highlight targeted cytotoxic delivery, but many oncogenic drivers are intracellular and inaccessible to antibodies.
- Small molecule inhibitors are currently used for intracellular targets but lack targeted delivery mechanisms.
- Developing novel strategies for targeted intracellular delivery of cytotoxic payloads is crucial for advancing cancer therapy.
Purpose of the Study:
- To explore repurposing small molecule inhibitors for intracellular delivery and controlled release of cytotoxic payloads.
- To develop a pre-targeting strategy using click-to-release chemistry for selective activation of caged prodrugs.
- To demonstrate the feasibility of this approach using an epidermal growth factor receptor (EGFR) targeted therapy.
Main Methods:
- Utilized click-to-release chemistry to create inhibitor-tetrazine conjugates for targeted activation.
- Developed systemically administered *trans*-cyclooctene (TCO) caged prodrugs for controlled payload release.
- Employed an afatinib-tetrazine conjugate to target EGFR-overexpressing cells and deliver a monomethyl auristatin E (MMAE) payload.
Main Results:
- Achieved sufficient intracellular retention of the afatinib-tetrazine conjugate in EGFR-overexpressing cells.
- Demonstrated successful toxicity recovery from a TCO-protected MMAE derivative upon intracellular activation.
- Validated the concept of targeted intracellular delivery and controlled release of cytotoxic payloads.
Conclusions:
- Repurposing small molecule inhibitors with click-to-release chemistry enables targeted intracellular delivery of cytotoxic payloads.
- This strategy allows for controlled payload release, overcoming limitations of traditional antibody-drug conjugates for intracellular targets.
- Establishes a foundation for expanding targeted drug delivery to previously inaccessible oncogenic drivers, improving cancer treatment efficacy.
Related Concept Videos
04:58Isolation of Cell-Surface and Intracellular Proteins from an Astrocyte Culture
10:26Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions
Intracellular Signaling Cascades
10:08Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
03:14Measuring Mast Cell Exocytosis via Neuropeptide Y Monomeric Red Fluorescent Protein Release
09:03Exploiting Live Imaging to Track Nuclei During Myoblast Differentiation and Fusion

